KRAS and non-small cell lung carcinoma: In a study of 933 patients with nonsquamous NSCLC, no patients with METex14 skipping mutations had activating mutations in KRAS, EGFR or ERBB2, or rearrangements involving ALK, ROS1 or RET [20].